

COMPANY SPOTLIGHT - INTEGRAL DIAGNOSTICS

Integral Diagnostics (IDX) is a diagnostic imaging company, providing scans for patients across Australia and New Zealand. Their network of clinics provides essential information for general practitioners, medical specialists and allied health professionals to effectively diagnose and manage a range of medical conditions including bone fractures, arthritis, cancer, stroke and heart disease.

IDX contributes to SDG3 Health by providing scans such as Magnetic Resonance Imaging (MRI) scans, Computerised Tomography (CT) scans and X-rays on behalf of over 35,000 medical referrers from 67 regional clinics across Australia and New Zealand. In addition to its radiology business, IDX also provides front-line treatment in some specific cases, such as Interventional Radiology in fitting stents.

We believe IDX has further opportunity for growth in expanding their clinic network and geographic coverage via further acquisitions. IDX is an established, efficient and well-regarded operator who have a successful track record in consolidating the fragmented Australian and New Zealand radiology markets.

Since 2019, Melior has engaged extensively with IDX on its ESG journey with specific focus around emissions reduction targets, modern slavery and diversity & inclusion including Reconciliation Action Plans given IDX's exposure to regional Australia. In August 2020, ESG became one of Integral Diagnostics five strategic pillars and the company published its inaugural ESG report.



Company Impact KPIs (FY21)

- Patients consulted: 797,000
- Examinations performed: 2 million
- Capital expenditure committed to improving access to MRI and CT scans in regional areas: \$23 million



FY21 Melior Annual Impact Report IDX Quote

“ In the ongoing development of our Environmental, Social and Governance strategy and initiatives, Melior has been a valued sounding board on the direction we've taken. We always have meaningful conversations with Melior on our own Environmental, Social and Governance journey as well as being kept abreast of developments and expectations of investors, society and governments around large companies responsibilities in this space. ”

ANNE LOCKWOOD, CHIEF FINANCIAL AND COMMERCIAL OFFICER

SDG Alignment:

SDG 3.4: IDX is a diagnostic imaging company that contributes to reducing “premature mortality from non-communicable diseases through prevention and treatment”

This Report has been prepared and issued by Melior Investment Management Pty Limited (ACN 629 013 896) (Melior) as the investment manager of the Melior Australian Impact Fund (Fund). The Trust Company (RE Services) Limited (ABN 45 003 278 831) is the responsible entity and issuer of units in the Fund. Melior is a Corporate Authorised Representative (No. 001274055) of Adamantem Capital Pty Limited (ACN 614 857 037, AFSL No. 492717). This information is general information only and is not intended to provide you with financial advice, and has been prepared without taking into account your objectives, financial situation or needs. You should consider the product disclosure statement (PDS) for the Fund, prior to making any investment decisions. The PDS and target market determination (TMD) can be obtained by calling +61 2 9004 6071 or visiting our website www.meliorim.com.au. If you require financial advice that takes into account your personal objectives, financial situation or needs, you should consult your licensed or authorised financial adviser. This information is only as current as the date indicated, and may be superseded by subsequent market events or for other reasons. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. All investments contain risk and may lose value.